Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675023 · ClinicalTrials.gov registry record · Phase 1
Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects
A Phase 1 study, sponsored by Momenta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 603
- Enrollment target
NCT02675023: Completed Phase 1 study, sponsored by Momenta Pharmaceuticals.
NCT02675023 is a Phase 1 study that has completed, run by Momenta Pharmaceuticals. The registered enrollment target is 603 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (905% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02675023, a Phase 1 study, has completed, sponsored by Momenta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 603 participants
- Enrollment target
Study Summary
This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg) subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe (PFS) in healthy subjects.
Primary Outcome
Area under the concentration-time curve in serum from time zero (predose) extrapolated to infinity \[AUC(0-inf)\]
Interventions
- BIOLOGICAL M923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
What the finished NCT02675023 record still lists
NCT02675023 is an interventional study that assigns participants to a tested intervention. The registered 603 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (905% higher).
The record links to 0 conditions, and to 1 intervention - of which M923 is the first listed.
NCT02675023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02675023 about?
NCT02675023 is a clinical study titled "Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects". This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg) subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe (PFS) in healthy subjects.
What is the current status of trial NCT02675023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 603 participants. The study started on 2016-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02675023?
The interventions under investigation include: M923 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02675023?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02675023's enrollment target sits among peer trials
603 27th of 2000 higher than 1,974 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia